Nose spray for sudden vision loss from optic nerve damage
Part of Brain & nervous system, Eyes & vision, Heart & circulation clinical trials.
This trial tests a nose spray medication (cenegermin) for people who recently lost vision due to a specific type of optic nerve damage (NAION). The goal is to see if it can help restore sight when started within two weeks of vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have sudden vision loss in one eye caused by a problem with the optic nerve (NAION), diagnosed by a doctor.
- Your vision loss must have started less than 14 days ago.
- Your vision in the affected eye should be between roughly 20/30 and 20/1000 on an eye chart.
- You cannot have vision loss in both eyes from this condition, or a history of giant cell arteritis.
- You must not have glaucoma or high eye pressure in the affected eye, or certain types of age-related macular degeneration.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug, ER-100, is safe for people with glaucoma or a sudden optic nerve injury called NAION. It aims to see if the drug can be given without serious side effects.
This study tests whether a new medication called privosegtor can help restore vision in people who recently experienced sudden vision loss in one eye due to optic nerve inflammation. You would receive the study drug early after your symptoms start, when treatment may be most effective.
This early-stage study tests an investigational drug called FB1001 for people who have recently experienced a type of sudden vision loss from either acute angle-closure glaucoma or a stroke-like event in the optic nerve (NAION). The treatment aims to protect the optic nerve and potentially preserve your remaining vision.
This study uses MRI scans to look at inflammation in blood vessels around the eye in two conditions: giant cell arteritis (GCA, a type of blood vessel inflammation) and ischemic optic neuropathy (a condition where the optic nerve doesn't get enough blood). The goal is to better understand how inflammation affects the optic nerve and vision, which could help guide future treatments.
This Phase 2 trial tests whether clemastine can help regrow the protective covering around the optic nerve after acute optic neuritis (an inflammation-related vision problem). It may help improve vision recovery and signal how well “remyelination” happens.
This trial tests whether NAD precursor supplements can improve nerve health and vision in people with glaucoma. If you have glaucoma with mild to moderate vision loss, this study may help understand if these supplements could protect your optic nerve.
Hear when a new Non-Arteritic Anterior Ischemic Optic Neuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.